Combination chemotherapy with docetaxel and carboplatin for elderly patients with endometrial cancer

Yoshida,Hiroyuki; Imai,Yuichi; Fujiwara,Keiichi

doi:10.3892/mco.2016.781

Combination chemotherapy with docetaxel and carboplatin for elderly patients with endometrial cancer

Authors:
- Hiroyuki Yoshida
- Yuichi Imai
- Keiichi Fujiwara
View Affiliations

Affiliations: Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan
Published online on: February 16, 2016 https://doi.org/10.3892/mco.2016.781
Pages: 783-788

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Approximately half of all endometrial cancer cases are diagnosed in patients aged >65 years. The objective of this study was to compare the tolerability and effectiveness of combination chemotherapy with docetaxel and carboplatin between endometrial cancer patients older and younger than 65 years of age. Chemotherapy‑naive patients with endometrial cancer were enrolled in this retrospective study between April, 2008 and March, 2015. The patients received docetaxel (60 mg̸m2) and carboplatin (area under the curve of 6 mg/ml̸min) on day 1 of a 3‑week cycle. The tolerability and effectiveness of this regimen were analyzed. A total of 41 patients with endometrial cancer were enrolled in this study, of whom 26 (63%) were aged <65 years and 15 (37%) were aged ≥65 years. There were no significant differences with regard to Eastern Cooperative Oncology Group performance status score and disease stage between the two groups. Patients aged >65 years were significantly more likely to have serous or clear‑cell histology and high‑grade tumors compared with the younger group (P=0.014 and 0.012, respectively). Although the number of chemotherapy cycles, cycle delays and treatment interruptions were comparable between older and younger patients, there was a trend toward more dose reductions in the older group (P=0.12). The incidence of hematological toxicities did not differ significantly between the two groups. The incidence of grade 3̸4 diarrhea was significantly higher in the older group (P=0.014) and hypersensitivity was significantly more frequent in the younger group (P=0.035). Patients aged ≥65 years had equivalent response rates, progression‑free survival and overall survival compared with those aged <65 years. These results suggest that combination chemotherapy with docetaxel and carboplatin was tolerable and effective for the treatment of elderly chemotherapy‑naive patients with endometrial cancer.

View Figures

View References

1	Monson K, Litvak DA and Bold RJ: Surgery in the aged population: Surgical oncology. Arch Surg. 138:1061–1067. 2003. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
3	Platz CE and Benda JA: Female genital tract cancer. Cancer. 75:270–294. 1995. View Article : Google Scholar : PubMed/NCBI
4	Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT and Benda JA: Gynecologic Oncology Group Study: Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 24:36–44. 2006. View Article : Google Scholar : PubMed/NCBI
5	Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A and Burks RT: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A gynecologic oncology group study. J Clin Oncol. 22:2159–2166. 2004. View Article : Google Scholar : PubMed/NCBI
6	Miller D, Fillaci V, Fleming G, Mannel R, Cohn D, Matsumoto T, Tewari K, DiSilvestro P, Pearl M and Zaino R: Randomized phase III noninferiority trial of first-line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 125:771–773. 2012. View Article : Google Scholar
7	Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, Jobo T, Hatae M, Hiura M and Yaegashi N: Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: A Japanese Gynecologic Oncology Group study (JGOG2041). Ann Oncol. 22:636–642. 2011. View Article : Google Scholar : PubMed/NCBI
8	ScribnerDR Jr, Puls LE and Gold MA: A phase II evaluation of docetaxel and carboplatin followed by tumor volume directed pelvic plus or minus paraaortic irradiation for stage III endometrial cancer. Gynecol Oncol. 125:388–393. 2012. View Article : Google Scholar : PubMed/NCBI
9	Geller MA, Ivy JJ, Ghebre R, Downs LS Jr, Judson PL, Carson LF, Jonson AL, Dusenbery K, Vogel RI, Boente MP, et al: A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a ‘sandwich’ method for stage III, IV and recurrent endometrial cancer. Gynecol Oncol. 121:112–117. 2011. View Article : Google Scholar : PubMed/NCBI
10	Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Kyoh S, Tochino Y, Asai K, Kodama T, Ichimaru Y, Yana T and Hirata K: Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. J Thorac Oncol. 4:371–375. 2009. View Article : Google Scholar : PubMed/NCBI
11	Kim HJ, Kim TG, Lee HJ, Kim JH, Lim BH, Seo JW, Kang EM, Lee BU, Ahn YM, Roh YH, et al: A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer. Lung Cancer. 68:248–252. 2010. View Article : Google Scholar : PubMed/NCBI
12	Kurt E, Cubukcu E, Karabulut B, Olmez OF, Kurt M, Avci N, Ozdemir F, Tunali D, Evrensel T and Manavoglu O: A multi-institutional evaluation of carboplatin plus docetaxel regimen in elderly patients with advanced gastric cancer. J BUON. 18:147–153. 2013.PubMed/NCBI
13	Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
14	Cockcroft DW and Gault MH: Prediction of clearance from serum creatinine. Nephron. 16:31–41. 1976. View Article : Google Scholar : PubMed/NCBI
15	National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40Accessed. June 21–2015
16	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
17	Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E and Sargent DJ: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 24:4085–4091. 2006. View Article : Google Scholar : PubMed/NCBI
18	Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B and Novotny WF: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol. 23:3697–3705. 2005. View Article : Google Scholar : PubMed/NCBI
19	Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN and Giordano SH: Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 25:3808–3815. 2007. View Article : Google Scholar : PubMed/NCBI
20	Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, et al: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 293:1073–1081. 2005. View Article : Google Scholar : PubMed/NCBI
21	Fairfield KM, Murray K, Lucas FL, Wierman HR, Earle CC, Trimble EL, Small L and Warren JL: Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. J Clin Oncol. 29:3921–3926. 2011. View Article : Google Scholar : PubMed/NCBI
22	Sundararajan V, Hershman D, Grann VR, Jacobson JS and Neugut AI: Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: A population-based study. J Clin Oncol. 20:173–178. 2002. View Article : Google Scholar : PubMed/NCBI
23	Eisenhauer EL, Tew WP, Levine DA, Lichtman SM, Brown CL, Aghajanian C, Huh J, Barakat RR and Chi DS: Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol. 106:381–387. 2007. View Article : Google Scholar : PubMed/NCBI
24	ten Tije AJ, Verweij J, Carducci MA, Graveland W, Rogers T, Pronk T, Verbruggen MP, Dawkins F and Baker SD: Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol. 23:1070–1077. 2005. View Article : Google Scholar : PubMed/NCBI
25	Italiano A, Ortholan C, Oudard S, Pouessel D, Gravis G, Beuzeboc P, Bompas E, Fléchon A, Joly F, Ferrero JM and Fizazi K: Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol. 55:1368–1375. 2009. View Article : Google Scholar : PubMed/NCBI
26	Belani CP and Fossella F: Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer. 104:2766–2774. 2005. View Article : Google Scholar : PubMed/NCBI
27	Fader AN, von Gruenigen V, Gibbons H, Abushahin F, Starks D, Markman M, Belinson J and Rose P: Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol. 109:33–38. 2008. View Article : Google Scholar : PubMed/NCBI